Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge

Letter Oncology

Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

Deepak B. Vangala et al.

LEUKEMIA (2023)

Article Oncology

Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studies

Marie-France Gagnon et al.

Summary: This study evaluated the genetic findings of 831 cases with APL and found that atypical genetic mechanisms leading to the oncogenic PML::RARA fusion exist in some cases. Additionally, other chromosome abnormalities were observed in some cases. These findings provide important information for APL research in both clinical and research laboratory settings.

GENES CHROMOSOMES & CANCER (2022)

添加到收藏夹

Article Oncology

Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias

Valentin Lestringant et al.

Summary: The study compared optical genome mapping (OGM) to standard techniques in detecting cytogenetic abnormalities in acute lymphoblastic leukemias (ALL). OGM showed higher accuracy and sensitivity, identifying anomalies not easily detectable by standard techniques.

GENES CHROMOSOMES & CANCER (2021)

添加到收藏夹

Letter Oncology

Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH

Jasmine Singh et al.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹

Review Oncology

Acute promyelocytic leukemia current treatment algorithms

Musa Yilmaz et al.

Summary: The article provides an overview of the history of acute promyelocytic leukemia (APL) and its treatment, including the main therapies used today such as all-trans retinoic acid (ATRA), chemotherapy, and arsenic trioxide combination therapy.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Letter Oncology